GlassScriptPhysician profile
Jeffrey R Dempsey
NPI 1063282549
$6,235.88
in general payments reported to CMS, 2019-2025
42 companies · $4,509 in 2025
The $4,509 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,727 · 2025: $4,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,294 · Travel and Lodging: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,294.06 |
| Travel and Lodging | $941.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,497.61 | 2025 | Minimed 780g, Intellis Adaptivestim |
| Lilly USA, LLC | $532.48 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $429.16 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $322.48 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Corcept Therapeutics | $258.96 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $234.70 | 2024-2025 | Xarelto, Spravato |
| Axsome Therapeutics, INC. | $230.34 | 2024-2025 | Auvelity |
| Dexcom, INC. | $188.66 | 2024-2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $188.32 | 2024 | Senza |
| Sanofi-Aventis U.S. LLC | $184.92 | 2025 | |
| Abbvie INC. | $175.52 | 2024-2025 | |
| Shield Therapeutics INC | $173.42 | 2024-2025 | |
| Amgen INC. | $171.67 | 2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.24 | 2024-2025 | Jardiance, Synjardy |
| Stryker Corporation | $146.20 | 2025 | Mako |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $141.97 | 2025 | Veozah |
| Tandem Diabetes Care, INC. | $141.75 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Phathom Pharmaceuticals, INC. | $139.62 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $125.23 | 2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $86.32 | 2024-2025 | |
| Cequr Corporation | $71.43 | 2024 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $58.27 | 2024-2025 | Strensiq |
| Inspire Medical Systems, INC. | $44.84 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $41.32 | 2024-2025 | Gemtesa |
| Ardelyx, INC. | $38.99 | 2024 | Ibsrela |
| Boston Scientific Corporation | $38.74 | 2025 | Ams 700 |
| Novartis Pharmaceuticals Corporation | $38.42 | 2024 | |
| Azurity Pharmaceuticals, INC. | $36.68 | 2025 | Edarbi |
| Exact Sciences Corporation | $34.74 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Tolmar, INC. | $34.39 | 2025 | Jatenzo |
| Recordati_rare_diseases_inc. | $32.56 | 2024-2025 | Isturisa, Signifor Lar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.38 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $31.26 | 2025 | |
| Edwards Lifesciences Corporation | $29.86 | 2025 | Sapien 3 Ultra Resilia |
| Madrigal Pharmaceuticals | $23.02 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $21.07 | 2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $18.70 | 2024 | Nuedexta |
| Averitas Pharma INC. | $17.27 | 2025 | Qutenza |
| Pfizer INC. | $15.39 | 2024 | |
| Merck Sharp & Dohme LLC | $14.33 | 2025 | Capvaxive, Gardasil 9 |
| Seqirus USA INC | $13.63 | 2024 | Fluad, Flucelvax |
| Organon LLC | $12.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Dempsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.